- Record: found
- Abstract: found
- Article: found
A Trial of Calcitonin Therapy in Renal Osteodystrophy
Barbara G. Delano , R. Baker , B. Gardner , S. Wallach
28 November 2008
Abstract
Synthetic salmon calcitonin (100 MRC units/day)was administered to three patients with chronic renal insufficiency supported by maintenance hemodialysis; these patients had also developed secondary hyperparathyroidism.The diagnosis of hyperparathyroidism was based on bone pain, X-ray changesindicating subperiosteal bone reabsorption, increased levels of serum alkaline phosphatase, accelerated radiocalcium turnover, increased resorption on bone biopsy and increased levels of bone cell collagenase activity. No improvement was noted in any of the measured parameters after 4–11 weeks of calcitonin therapy. A further increase in serum alkaline phosphatase occurred in one patient and bone cell collagenase activity increased further in all three patients. These data suggest that calcitonin may exaggerate the secondary hyperparathyroidism of chronic renal failure and, therefore, is not therapeutically useful.
Related collections
Author and article information
Journal
Affiliations
Article
180236 Nephron 1973;11:287–293Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.